Oncology Molecular Diagnostics Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis (2017-2021) and Forecast (2022-2028)

$ PRICE - $ 3,000.00$ 8,900.00

Oncology Molecular Diagnostics Market: By Type (Breast Cancer, Prostate Cancer, Colorectal Cancer, Cervical Cancer, Liver Cancer, Lung Cancer, Blood Cancer, Kidney Cancer, Others), By Product (Instruments, Reagents, Others), By Test Location ( Clinics and Other Establishments, Others), By Technology ( PCR, In Situ Hybridization, Isothermal Nucleic Acid Amplification Technology (INAAT), Chips & Microarrays, Chips & Microarrays, Sequencing, Transcription Mediated Amplification, Others) and Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail

Report

Description

Oncology Molecular Diagnostics Market size is valued at USD 3.63 billion in 2021 and expected to reach a value of USD 8.32 billion by 2028, growing at a CAGR of 12.6% during the forecast period 2022-28 . The global market provides a detailed overview of the Oncology Molecular Diagnostics market and that can be segmented by type, product, test location, and technology. By type, The Oncology Molecular Diagnostics market has been segmented into Breast Cancer, Prostate Cancer, Colorectal Cancer, Cervical Cancer, Liver Cancer, Lung Cancer, Blood Cancer, Kidney Cancer, and Others. The Brest cancer segment is likely to be the largest and fastest-growing segment in terms of type. Based on product the Oncology Molecular Diagnostics Market is segmented into Instruments, Reagents, and Others.  Among these, the reagents segment is expected to have the fastest-growing market during the forecast period 2022-2028. Based on the test location, the Oncology Molecular Diagnostics Market is segmented into Clinics and Other Establishments, Others. The clinic segment accounts for the largest share in 2021.

 

Key Development:

In February 2020, Danaher (Cepheid) announced a collaboration with Sherlock Biosciences to explore the innovative, ground-breaking molecular diagnostic test development intended for oncology and infectious diseases deploying CRISPR technology.

Oncology Molecular Diagnostics Market

MARKET SUMMARY
-
12.6% CAGR
  • Study Period– 2022-2028
  • Base Year– 2021
  • CAGR– 12.6%
  • Largest Market– North-America
  • Fastest Growing Market– Asia-Pacific

Oncology Molecular Diagnostics Market

  • The oncology molecular diagnostics market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • The oncology molecular diagnostics market is segmented based on product type, test location, technology and geography.
Key Players
  • Abbott Laboratories,
  • Bayer Healthcare AG,
  • Beckman Coulter, Inc.,
  • Cepheid, Inc
  • Becton, Dickinson and Company,
Oncology Molecular Diagnostics Market

Drivers

Increase in the prevalence of cancers such as breast cancer in women and prostate cancer is men is the major factor anticipated to burgeon the oncology molecular diagnostics market over the forecast years. Moreover, rise in R&D for the development of point of care diagnostic test kits, government initiatives for the cancer screening programs, and the launch of advanced test kits are immense boost to the market over the forecast timeframe.


North-America Got Significant Share

Oncology Molecular Diagnostics Market

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East
Oncology Molecular Diagnostics Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

The Oncology Molecular Diagnostics Market is projected to expand at a CAGR of 12.6% during the forecast period.

The major players in the global oncology molecular diagnostics market are Abbott Laboratories, Bayer Healthcare AG, Beckman Coulter, Inc., Becton, Dickinson and Company, Cepheid, Inc., Danaher Corporation, Hologic, Inc., Leica Biosystems Inc., Qiagen NV, Roche Diagnostics (Schweiz) AG, Siemens Healthineers, Sysmex Corporation

Asia-Pacific is the fastest-growing region for Oncology Molecular Diagnostics Market


Report

Table Of Content

1. Executive Summary
2. Global Oncology Molecular Diagnostics Market Introduction
2.1. Global Oncology Molecular Diagnostics Market – Taxonomy
2.2. Global Oncology Molecular Diagnostics Market –Definitions
2.2.1. By Type
2.2.2. By Product
2.2.3. By Test Location
2.2.4. By Technology
2.2.5. By Region
3. Global Oncology Molecular Diagnostics Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Oncology Molecular Diagnostics Market Dynamic Factors – Impact Analysis
3.6. Global Oncology Molecular Diagnostics Market – Competition Landscape
3.7. Epidemiology Data
4. Global Oncology Molecular Diagnostics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028
4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Oncology Molecular Diagnostics Market, By Type, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.1. Breast Cancer
5.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Prostate Cancer
5.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Colorectal Cancer
5.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Cervical Cancer
5.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Liver Cancer
5.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Lung Cancer
5.6.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
5.7. Blood Cancer
5.7.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.7.3. Market Opportunity Analysis
5.8. Kidney Cancer
5.8.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.8.3. Market Opportunity Analysis
5.9. Others
5.9.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.9.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.9.3. Market Opportunity Analysis
6. Global Oncology Molecular Diagnostics Market, By Product, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.1. Instruments
6.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Reagents
6.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Others
6.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
7. Global Oncology Molecular Diagnostics Market, By Test Location, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.1. Clinics and Other Establishments
7.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Others
7.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
8. Global Oncology Molecular Diagnostics Market, By Technology, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.1. PCR
8.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. In Situ Hybridization
8.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Isothermal Nucleic Acid Amplification Technology (INAAT)
8.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Chips & Microarrays
8.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Mass Spectroscopy
8.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Sequencing
8.6.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.6.3. Market Opportunity Analysis
8.7. Transcription Mediated Amplification
8.7.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.7.3. Market Opportunity Analysis
8.8. Others
8.8.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.8.3. Market Opportunity Analysis
9. Global Oncology Molecular Diagnostics Market Forecast, By Region, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
9.1. North America
9.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.1.3. Market Opportunity Analysis
9.2. Europe
9.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.2.3. Market Opportunity Analysis
9.3. Asia-Pacific
9.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.3.3. Market Opportunity Analysis
9.4. Latin America
9.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.4.3. Market Opportunity Analysis
9.5. Middle East and Africa
9.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.5.3. Market Opportunity Analysis
9.6. Global Oncology Molecular Diagnostics Market – Opportunity Analysis Index, By Type, By Resin, By Application, and Region, 2022 – 2028
10. North America Oncology Molecular Diagnostics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
10.1. Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Breast cancer
10.1.2. Prostate cancer
10.1.3. Colorectal cancer
10.1.4. Cervical cancer
10.1.5. Liver cancer
10.1.6. Lung cancer
10.1.7. Blood cancer
10.1.8. Kidney cancer
10.1.9. Others
10.2. Product Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Instruments
10.2.2. Reagents
10.2.3. Others
10.3. Test Location Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Clinics and other establishments
10.3.2. Point of Care
10.4. Technology Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.4.1. PCR
10.4.1.1. Multiplex
10.4.1.2. Others
10.4.2. In Situ Hybridization
10.4.3. Isothermal Nucleic Acid Amplification Technology (INAAT)
10.4.4. Chips and microarrays
10.4.5. Mass spectrometry
10.4.6. Sequencing
10.4.7. Transcription Mediated Amplification
10.4.8. Others
10.5. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.5.1. U.S.
10.5.2. Canada
10.6. North America Oncology Molecular Diagnostics Market – Opportunity Analysis Index, By Type, Product, Test Location, Technology, And Country, 2022 – 2028
10.7. North America Oncology Molecular Diagnostics Market Dynamics – Trends
11. Europe Oncology Molecular Diagnostics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
11.1. Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Breast cancer
11.1.2. Prostate cancer
11.1.3. Colorectal cancer
11.1.4. Cervical cancer
11.1.5. Liver cancer
11.1.6. Lung cancer
11.1.7. Blood cancer
11.1.8. Kidney cancer
11.1.9. Others
11.2. Product Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Instruments
11.2.2. Reagents
11.2.3. Others
11.3. Test Location Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Clinics and other establishments
11.3.2. Point of Care
11.4. Technology Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.4.1. PCR
11.4.1.1. Multiplex
11.4.1.2. Others
11.4.2. In Situ Hybridization
11.4.3. Isothermal Nucleic Acid Amplification Technology (INAAT)
11.4.4. Chips and microarrays
11.4.5. Mass spectrometry
11.4.6. Sequencing
11.4.7. Transcription Mediated Amplification
11.4.8. Others
11.5. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.5.1. Germany
11.5.2. UK
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Russia
11.5.7. Poland
11.5.8. Rest of Europe
11.6. Europe Oncology Molecular Diagnostics Market – Opportunity Analysis Index, By Type, Product, Test Location, Technology, And Country, 2022 – 2028
11.7. Europe Oncology Molecular Diagnostics Market Dynamics – Trends
12. Asia-Pacific Oncology Molecular Diagnostics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
12.1. Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Breast cancer
12.1.2. Prostate cancer
12.1.3. Colorectal cancer
12.1.4. Cervical cancer
12.1.5. Liver cancer
12.1.6. Lung cancer
12.1.7. Blood cancer
12.1.8. Kidney cancer
12.1.9. Others
12.2. Product Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Instruments
12.2.2. Reagents
12.2.3. Others
12.3. Test Location Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Clinics and other establishments
12.3.2. Point of Care
12.4. Technology Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.4.1. PCR
12.4.1.1. Multiplex
12.4.1.2. Others
12.4.2. In Situ Hybridization
12.4.3. Isothermal Nucleic Acid Amplification Technology (INAAT)
12.4.4. Chips and microarrays
12.4.5. Mass spectrometry
12.4.6. Sequencing
12.4.7. Transcription Mediated Amplification
12.4.8. Others
12.5. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.5.1. Japan
12.5.2. China
12.5.3. India
12.5.4. ASEAN
12.5.5. Australia & New Zealand
12.5.6. Rest of Asia-Pacific
12.6. Asia-Pacific Oncology Molecular Diagnostics Market – Opportunity Analysis Index, By Type, Product, Test Location, Technology, And Country, 2022 – 2028
12.7. Asia-Pacific Oncology Molecular Diagnostics Market Dynamics – Trends
13. Latin America Oncology Molecular Diagnostics Market Analysis, 2017 – 2021 and Forecast, 2020 – 2026
13.1. Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Breast cancer
13.1.2. Prostate cancer
13.1.3. Colorectal cancer
13.1.4. Cervical cancer
13.1.5. Liver cancer
13.1.6. Lung cancer
13.1.7. Blood cancer
13.1.8. Kidney cancer
13.1.9. Others
13.2. Product Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Instruments
13.2.2. Reagents
13.2.3. Others
13.3. Test Location Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Clinics and other establishments
13.3.2. Point of Care
13.4. Technology Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.4.1. PCR
13.4.1.1. Multiplex
13.4.1.2. Others
13.4.2. In Situ Hybridization
13.4.3. Isothermal Nucleic Acid Amplification Technology (INAAT)
13.4.4. Chips and microarrays
13.4.5. Mass spectrometry
13.4.6. Sequencing
13.4.7. Transcription Mediated Amplification
13.4.8. Others
13.5. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Argentina
13.5.4. Rest of Latin America
13.6. Latin America Oncology Molecular Diagnostics Market – Opportunity Analysis Index, By Type, Product, Test Location, Technology, And Country, 2022 – 2028
13.7. Latin America Oncology Molecular Diagnostics Market Dynamics – Trends
14. Middle East and Africa Oncology Molecular Diagnostics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
14.1. Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.1.1. Breast cancer
14.1.2. Prostate cancer
14.1.3. Colorectal cancer
14.1.4. Cervical cancer
14.1.5. Liver cancer
14.1.6. Lung cancer
14.1.7. Blood cancer
14.1.8. Kidney cancer
14.1.9. Others
14.2. Product Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.2.1. Instruments
14.2.2. Reagents
14.2.3. Others
14.3. Test Location Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.3.1. Clinics and other establishments
14.3.2. Point of Care
14.4. Technology Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.4.1. PCR
14.4.1.1. Multiplex
14.4.1.2. Others
14.4.2. In Situ Hybridization
14.4.3. Isothermal Nucleic Acid Amplification Technology (INAAT)
14.4.4. Chips and microarrays
14.4.5. Mass spectrometry
14.4.6. Sequencing
14.4.7. Transcription Mediated Amplification
14.4.8. Others
14.5. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
14.5.1. Gulf Cooperation Council (GCC) Countries
14.5.2. Israel
14.5.3. South Africa
14.5.4. Rest of MEA
14.6. MEA Oncology Molecular Diagnostics Market – Opportunity Analysis Index, By Type, Product, Test Location, Technology, And Country, 2022 – 2028
14.7. MEA Oncology Molecular Diagnostics Market Dynamics – Trends
15. Competition Landscape 
15.1. Strategic Dashboard of Top Market Players
15.1.1. Company Profiles (Introduction, Financial Analysis, Key Developments, Strategies, and SWOT Analysis)
15.1.2. Abbott Laboratories
15.1.3. Bayer Healthcare AG
15.1.4. Beckman Coulter, Inc.
15.1.5. Becton, Dickinson and Company
15.1.6. Cepheid, Inc.
15.1.7. Danaher Corporation
15.1.8. Hologic, Inc.
15.1.9. Leica Biosystems Inc.
15.1.10. Qiagen NV
15.1.11. Roche Diagnostics (Schweiz) AG
15.1.12. Siemens Healthineers
15.1.13. Sysmex Corporation
16. Research Methodology
17. Key Assumptions and Acronyms

Report

Company Profile

  • Abbott Laboratories
  • Bayer Healthcare AG
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • Cepheid, Inc.
  • Danaher Corporation
  • Hologic, Inc.
  • Leica Biosystems Inc.
  • Qiagen NV
  • Roche Diagnostics (Schweiz) AG
  • Siemens Healthineers
  • Sysmex Corporation

Description

Oncology Molecular Diagnostics Market size is valued at USD 3.63 billion in 2021 and expected to reach a value of USD 8.32 billion by 2028, growing at a CAGR of 12.6% during the forecast period 2022-28 . The global market provides a detailed overview of the Oncology Molecular Diagnostics market and that can be segmented by type, product, test location, and technology. By type, The Oncology Molecular Diagnostics market has been segmented into Breast Cancer, Prostate Cancer, Colorectal Cancer, Cervical Cancer, Liver Cancer, Lung Cancer, Blood Cancer, Kidney Cancer, and Others. The Brest cancer segment is likely to be the largest and fastest-growing segment in terms of type. Based on product the Oncology Molecular Diagnostics Market is segmented into Instruments, Reagents, and Others.  Among these, the reagents segment is expected to have the fastest-growing market during the forecast period 2022-2028. Based on the test location, the Oncology Molecular Diagnostics Market is segmented into Clinics and Other Establishments, Others. The clinic segment accounts for the largest share in 2021.

 

Key Development:

In February 2020, Danaher (Cepheid) announced a collaboration with Sherlock Biosciences to explore the innovative, ground-breaking molecular diagnostic test development intended for oncology and infectious diseases deploying CRISPR technology.

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX